INTRODUCTION: Insight into the relationship between concepts that matter to the people affected by Alzheimer’s disease (AD) and the clinical outcome assessments (COAs) commonly used in AD clinical studies is limited. Phases 1 and 2 of the What Matters Most (WMM) study series identified and quantitatively confirmed 42 treatment-related outcomes that are important to people affected by AD. RESULTS: Twenty COAs designed to assess signs, symptoms, and impacts across the spectrum of AD were selected for review. Among these 20 COAs, only 5 reflected 12 or more WMM concepts (Integrated Alzheimer's Disease Rating Scale [iADRS], Alzheimer's Disease Cooperative Study–Activities of Daily Living Inventory [ADCS-ADL], Alzheimer's Disease Cooperative Study–Activities of Daily Living Inventory–Mild Cognitive Impairment [ADCS-ADL-MCI], Alzheimer's Disease Composite Scores [ADCOMS], and Clinical Dementia Rating; Clinical Dementia Rating-Sum of Boxes [CDR/CDR-SB]). Multiple symptoms and impacts of AD identified as important and meaningful in the WMM studies map only indirectly at best to 7 of the 20 most widely used COAs. CONCLUSION: While many frequently used COAs in AD capture some concepts identified as important to AD populations and their care partners, overlap between any single measure and the concepts that matter to people affected by AD is limited. The highest singly matched COA reflects fewer than half (45%) of WMM concepts. Use of multiple COAs expands coverage of meaningful concepts. Future research should explore the content validity of AD COAs planned for AD trials based on further confirmation of the ecological validity of the WMM items. This research should inform development and use of core outcome sets that capture WMM items and selection or development of new companion tools to fully demonstrate clinically meaningful outcomes spanning WMM.
METHODS: We compared WMM concepts rated as “very important” or higher to items included in COAs used commonly in AD studies.
